21 completed. 21 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 21 | Completed 21 |
| Phase 2 | 3 | Completed 3 |
Follow Systemic Vasculitis: new trials by email Literature Review of Systemic Vasculitis trials Research Report on Systemic Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) Mepolizumab, cyclophosphamide/azathioprine, Placebo - Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 102 | 2022-05-30 | 2026-10-01 |
| Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis Rituximab, placebo - Microscopic Polyangiitis (MPA) | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 8 | 2020-10-24 | 2026-05-06 |
| Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Rituximab, Azathioprine, Placebo-rituximab - Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 98 | 2018-03-07 | 2025-11-20 |
| A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Avacopan, Prednisone, Cyclophosphamide - ANCA-Associated Vasculitis | Phase 3 | Completed | Amgen | 331 | 2017-03-15 | 2025-03-24 |
| Rituximab in Eosinophilic Granulomatosis With Polyangiitis Rituximab, Placebo-rituximab, Cyclophosphamide - Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 107 | 2016-12-05 | 2026-01-15 |
| Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) Abatacept, placebo - Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis | Phase 3 | Completed | University of South Florida | 65 | 2015-04-25 | 2024-07-29 |
| Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Mepolizumab, Prednisolone - Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | Completed | GlaxoSmithKline | 100 | 2015-04-14 | 2024-03-12 |
| Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab rituximab, Placebo - ANCA-associated Vasculitides | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 97 | 2015-03-31 | 2025-11-20 |
| A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis Mepolizumab, Placebo - Churg-Strauss Syndrome | Phase 3 | Completed | GlaxoSmithKline | 136 | 2014-02-05 | 2018-01-31 |
| The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach 5 mg Prednisone, 0 mg Prednisone - Granulomatosis With Polyangiitis | Phase 3 | Completed | University of Pennsylvania | 159 | 2014-02-01 | 2026-08-06 |
| Rituximab Vasculitis Maintenance Study Rituximab, Azathioprine - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis | Phase 3 | Completed | Cambridge University Hospitals NHS Foundation Trust | 188 | 2013-04-01 | 2022-03-18 |
| Belimumab in Remission of VASculitis Placebo, Belimumab 10 mg/kg, Azathioprine - Vasculitis | Phase 3 | Completed | Human Genome Sciences Inc., a GSK Company | 106 | 2013-03-20 | 2018-04-17 |
| Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Rituximab (Arm B), Rituximab (Arm A) - Granulomatosis With Polyangiitis, Microscopic Polyangiitis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 166 | 2012-11-16 | 2025-09-05 |
| Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis Plasma Exchange, No Plasma Exchange, Glucocorticoids [Standard Dose] - Granulomatosis With Polyangiitis (Wegener's) (GPA), Microscopic Polyangiitis (MPA) | Phase 3 | Completed | University of Pennsylvania | 704 | 2010-05-01 | 2020-05-26 |
| Efficacy Study of Two Treatments in the Remission of Vasculitis Rituximab, Azathioprine - Wegener Granulomatosis, Microscopic Polyangiitis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 117 | 2008-10-01 | 2025-11-20 |
| Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) corticosteroid and azathioprine, corticosteroid and placebo - MPA, PAN or EGPA With FFS=0 | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 114 | 2008-05-01 | 2025-09-12 |
| Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Rituximab plus cyclophosphamide placebo (rituximab group), Cyclophosphamide plus rituximab placebo (control group), Azathioprine - Vasculitis, Wegener's Granulomatosis | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 197 | 2005-01-01 | 2017-04-21 |
| Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA) mycophenolate mofetil, cyclophosphamide - Wegener's Granulomatosis, Vasculitis | Phase 3 | Completed | University Medical Center Groningen | 84 | 2004-12-01 | 2024-08-27 |
| Etanercept for Wegener's Granulomatosis Etanercept - Wegener's Granulomatosis | Phase 2 / Phase 3 | Completed | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 181 | 2000-06-01 | 2007-12-28 |
| Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Alendronate versus alfacalcidol (1-alpha OH vitamin D) - Rheumatoid Arthritis, Polymyalgia Rheumatica | Phase 3 | Completed | UMC Utrecht | 200 | 2000-05-01 | 2006-11-29 |
Showing 20 of 21. Sign in to see all of them.
Granulomatosis with Polyangiitis (13) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (11) · Microscopic Polyangiitis (11) · Vasculitis (11) · Churg-Strauss Syndrome (6) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Giant Cell Arteritis (1) · Lung Diseases (1) · Polyarteritis Nodosa (1) · Polymyalgia Rheumatica (1) · Polymyositis (1) · Respiratory Tract Diseases (1) · Rheumatic Diseases (1)
Cardiovascular Diseases (21) · Immune System Diseases (21) · Skin Diseases (21) · Skin Diseases, Vascular (21) · Skin and Connective Tissue Diseases (21) · Autoimmune Diseases (20) · Vascular Diseases (20) · Lung Diseases, Interstitial (13) · Brain Diseases (12) · Central Nervous System Diseases (12) · Cerebrovascular Disorders (12) · Lung Diseases (12) · Nervous System Diseases (12) · Respiratory Tract Diseases (12)
Rituximab (9) · Azathioprine (8) · Cyclophosphamide (6) · Prednisone (3) · mepolizumab (3) · Glucocorticoids (2) · Abatacept (1) · Adrenal Cortex Hormones (1) · Control Groups (1) · Etanercept (1) · Methylprednisolone (1) · Mycophenolic Acid (1) · Plasma Exchange (1) · Prednisolone (1) · Sodium Chloride (1)
Assistance Publique - Hôpitaux de Paris (8) · Cambridge University Hospitals NHS Foundation Trust (2) · GlaxoSmithKline (2) · University of Pennsylvania (2) · Amgen (1) · Human Genome Sciences Inc., a GSK Company (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · UMC Utrecht (1) · University Medical Center Groningen (1) · University of South Florida (1)
France (13) · United States (10) · Canada (8) · United Kingdom (7) · Belgium (5) · Germany (5) · Italy (5) · Japan (5) · Australia (4) · Czechia (4) · Ireland (4) · Netherlands (4) · Sweden (4) · New Zealand (3) · Norway (3)
Loic Guillevin, MD, PhD (3) · John H. Stone, MD, MPH (2) · Peter A Merkel, MD, MPH (2) · Benjamin Terrier (1) · Carol A Langford, MD, MHS (1) · Caroline OS Savage (1) · Coen Stegeman, MD PhD (1) · David Jayne (1) · David Jayne, MD (1) · Jeffery P Krischer, PhD (1) · Jeffrey P Krischer, PhD (1) · Kirsten de Groot (1)
PMID 12905485, PMID 15751091, PMID 15838068, PMID 15986348, PMID 16378799, PMID 16646004, PMID 16914703, PMID 17407214, PMID 17557758, PMID 19451574, PMID 20647199, PMID 22127969, PMID 22975753, PMID 23754238, PMID 23902481, PMID 25047592, PMID 25372085, PMID 25776953, PMID 26387933, PMID 26621483, PMID 27049404, PMID 27696762, PMID 28270229, PMID 28514601, PMID 28592297, PMID 28678392, PMID 29695500, PMID 29724729, PMID 30666823, PMID 31056661, PMID 31216123, PMID 32053298, PMID 32088663, PMID 32479166, PMID 33367837, PMID 33596356, PMID 34618687, PMID 35167187, PMID 36155131, PMID 36958796, PMID 37134130, PMID 37903568, PMID 37979959, PMID 38346237, PMID 39425055, PMID 40008472, PMID 40720835, PMID 41052893
2016 (2), U54AR057319 (2), 2009 (1), 2014 (1), 2018 (1), R01HL115041 (1)